Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Packer, Milton, Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart J., Carson, Peter, Januzzi, James, Verma, Subodh, Tsutsui, Hiroyuki, Brueckmann, Martina, Jamal, Waheed, Kimura, Karen, Schnee, Janet, Zeller, Cordula, Cotton, Daniel, Bocchi, Edimar, Böhm, Michael, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Janssens, Stefan, Zhang, Jian, Gonzalez Juanatey, Jose R., Kaul, Sanjay, Brunner-La Rocca, Hans-Peter, Merkely, Bela, Nicholls, Stephen J., Perrone, Sergio, Pina, Ileana, Ponikowski, Piotr, Sattar, Naveed, Senni, Michele, Seronde, Marie-France, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Wanner, Christoph, Zannad, Faiez·2020·New England Journal of Medicine
DOI 10.1056/nejmoa2022190

Cited by (1,012)

Items 301–400 of 1,012

  1. Management of Obesity in Cardiovascular Practice
    Després, Jean-Pierre, Carpentier, André C., Tchernof, André, Neeland, Ian J., Poirier, Paul · 2021 · Journal of the American College of Cardiology
  2. Edema formation in congestive heart failure and the underlying mechanisms
    Zaid A. Abassi, Emad E. Khoury, Tony Karram, Doron Aronson · 2022 · Frontiers in Cardiovascular Medicine
  3. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
    Yehuda Handelsman, John E. Anderson, George L. Bakris, Christie Mitchell Ballantyne, Deepak L. Bhatt, Zachary T. Bloomgarden, Biykem Bozkurt, Matthew Jay Budoff, Javed Butler, David Z.I. Cherney et al. · 2024 · Metabolism
  4. Clinical features, treatment, and prognosis of SGLT2 inhibitors induced acute pancreatitis
    Ronghui Li, Panpan Luo, Yuge Guo, Yang He, Chunjiang Wang · 2024 · Expert Opinion on Drug Safety
  5. Heart failure: assessment of the global economic burden
    Mohammad Darvish, Abdul Shakoor, Lida Feyz, Jeroen Schaap, Nicolas M. Van Mieghem, Rudolf A. de Boer, Jasper Jan Brugts, Robert M. A. van der Boon · 2025 · European Heart Journal
  6. Sodium‐glucose co‐transporter‐2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials
    Victor Okunrintemi, Basem M. Mishriky, James R. Powell, Doyle M. Cummings · 2020 · Diabetes Obesity and Metabolism
  7. SGLT2 Inhibitors and Cardiac Remodelling: A Systematic Review and Meta-Analysis of Randomized Cardiac Magnetic Resonance Imaging Trials
    Nitish K. Dhingra, Nikhil Mistry, Pankaj Puar, Raj Verma, Stefan D. Anker, C. David Mazer, Subodh Verma · 2021 · ESC Heart Failure
  8. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
    Packer, Milton, Butler, Javed, Zeller, Cordula, Pocock, Stuart J., Brueckmann, Martina, Ferreira, João Pedro, Filippatos, Gerasimos, Usman, Muhammad Shariq, Zannad, Faiez, Anker, Stefan D. · 2023 · Circulation
  9. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis
    Bhattarai, Mukul, Salih, Mohsin, Regmi, Manjari, Al-Akchar, Mohammad, Deshpande, Radhika, Niaz, Zurain, Kulkarni, Abhishek, Siddique, Momin, Hegde, Shruti · 2022 · JAMA Network Open
  10. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial
    Fitchett, David, Inzucchi, Silvio E., Zinman, Bernard, Wanner, Christoph, Schumacher, Martin, Schmoor, Claudia, Ohneberg, Kristin, Ofstad, Anne Pernille, Salsali, Afshin, George, Jyothis T. et al. · 2021 · ESC Heart Failure
  11. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
    Francesco Giorgino, Jiten P Vora, Peter Fenici, Anna Solini · 2020 · Cardiovascular Diabetology
  12. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney
    Qingqing Ke, Caifeng Shi, Yunhui Lv, Lulu Wang, Jing Luo, Lei Jiang, Junwei Yang, Yang Zhou · 2021 · The FASEB Journal
  13. Advanced Heart Failure: Guideline-Directed Medical Therapy, Diuretics, Inotropes, and Palliative Care
    Daniela Tomasoni, Julie K.K. Vishram‐Nielsen, Matteo Pagnesi, Marianna Adamo, Carlo Lombardi, Finn Gustafsson, Marco Metra · 2022 · ESC Heart Failure
  14. Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease
    Hongyan Liu, Vikas S. Sridhar, Jacinthe Boulet, Atit Dharia, Abid Ali Khan, Patrick R. Lawler, David Z.I. Cherney · 2021 · Metabolism
  15. Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
    Mona Fiuzat, CARINE E. HAMO, Javed Butler, William T. Abraham, Ersilia M. DeFilippis, Gregg C. Fonarow, JoAnn M. Lindenfeld, Robert John Mentz, Mitchell A. Psotka, Scott David Solomon et al. · 2022 · Journal of the American College of Cardiology
  16. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement
    Stefano Romeo, Antonio Vidal‐Puig, Mansoor Husain, Rexford S. Ahima, Marcello Arca, Deepak L. Bhatt, Anna Mae Diehl, Luigi Fontana, Roger Foo, Gema Frühbeck et al. · 2025 · European Heart Journal
  17. Heart Failure Association of the European Society of Cardiology Update on Sodium–Glucose Co-Transporter 2 Inhibitors in Heart Failure
    Petar M Seferovic, Gabriele Fragasso, Mark Colquhoun Petrie, Wilfried Müllens, Roberto Ferrari, Thomas Thum, Johann K Bauersachs, Stefan D. Anker, Robin Ray, Yüksel Çavuşoğlu et al. · 2020 · European Journal of Heart Failure
  18. Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments
    Kazuomi Kario, Bryan Williams · 2021 · Hypertension
  19. Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
    Jawad H. Butt, Kieran F. Docherty, Pardeep S. Jhund, Rudolf A. de Boer, Michael Böhm, Akshay Suvas Desai, Jonathan G. Howlett, Silvio E. Inzucchi, Mikhail Kosiborod, Felipe A. Martínez et al. · 2021 · European Journal of Heart Failure
  20. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐ Reduced
    João Pedro Ferreira, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, Tomoko Iwata, Afshin Salsali, Cordula Zeller, Stuart Pocock, Faiez M. Zannad, Milton Packer · 2021 · European Journal of Heart Failure
  21. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis
    Husam M. Salah, Subhi Jamal Alaref, Muhammad Shahzeb Khan, Malek Al‐Hawwas, Srikanth Vallurupalli, Jawahar L. Mehta, John Paul Mounsey, Stephen John Greene, Darren K. McGuire, Renato D. Lópes et al. · 2022 · Cardiovascular Diabetology
  22. The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
    Katharina Andrea Schuett, Nikolaus Marx, Michael Lehrke · 2023 · Circulation Research
  23. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure
    Shunsuke Tamaki, Takahisa Yamada, Tetsuya Watanabe, Takashi Morita, Yoshio Furukawa, Masato Kawasaki, Atsushi Kikuchi, Tsutomu Kawai, Masahiro Seo, Makoto Abe et al. · 2021 · Circulation Heart Failure
  24. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes
    Min Zhuo, Julie M. Paik, Deborah J. Wexler, Joseph Vincent Bonventre, Seoyoung C. Kim, Elisabetta Patorno · 2021 · American Journal of Kidney Diseases
  25. Cognitive Impairment in Heart Failure: Landscape, Challenges, and Future Directions
    Mengxi Yang, Di Sun, Yu Wang, Mengwen Yan, Jingang Zheng, Jingyi Ren · 2022 · Frontiers in Cardiovascular Medicine
  26. Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
    Rujie Zheng, Yue Wang, Junnan Tang, Jie-Ying Duan, Ming-Yue Yuan, Jinying Zhang · 2021 · Journal of Cardiovascular Pharmacology
  27. Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
    Adriaan A. Voors, Kevin Damman, John R. Teerlink, Christiane E. Angermann, Sean P. Collins, Mikhail Kosiborod, Jan Biegus, João Pedro Ferreira, Michael E. Nassif, Mitchell A. Psotka et al. · 2022 · European Journal of Heart Failure
  28. Diretriz da SBC sobre Diagnóstico e Tratamento de Pacientes com Cardiomiopatia da Doença de Chagas – 2023
    José Antônio Marin‐Neto, Anis Rassi, Gláucia Maria Moraes de Oliveira, Luís Cláudio Lemos Correia, Alberto Novaes Ramos, Alejandro O. Luquetti, Alejandro Marcel Hasslocher‐Moreno, Andréa Silvestre de Sousa, Ângelo Amato Vincenzo de Paola, Antônio Carlos Sobral Sousa et al. · 2023 · Arquivos Brasileiros de Cardiologia
  29. Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
    Neuen, Brendon L., Arnott, Clare, Perkovic, Vlado, Figtree, Gemma, de Zeeuw, Dick, Fulcher, Greg, Jun, Min, Jardine, Meg J., Zoungas, Sophia, Pollock, Carol et al. · 2021 · Diabetes, Obesity and Metabolism
  30. Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension
    Alexandros Kasiakogias, Enrico Agabiti Rosei, Miguel Camafort, Georg Ehret, Luca Faconti, João Pedro Ferreira, Jana Brguljan-Hitij, Andrzej Januszewicz, Thomas Kahan, Athanasios John Manolis et al. · 2021 · Journal of Hypertension
  31. Towards precision medicine in heart failure
    Chad S. Weldy, Euan Angus Ashley · 2021 · Nature Reviews Cardiology
  32. Empagliflozin restores chronic kidney disease–induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction
    Rio P. Juni, Rushd Al‐Shama, Diederik W.D. Kuster, Jolanda van der Velden, Henrike M. Hamer, Marc G. Vervloet, Etto C. Eringa, Pieter Koolwijk, Victor W.M. van Hinsbergh · 2020 · Kidney International
  33. Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction
    Sam Straw, Melanie McGinlay, Klaus Karl Witte · 2021 · Open Heart
  34. Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community
    Adam J. Nelson, Neha Jadeja Pagidipati, Vanita R. Aroda, Matthew Aaron Cavender, Jennifer B. Green, Renato D. Lópes, Hussein R. Al‐Khalidi, Tanya Gaynor, Lisa A. Kaltenbach, Julienne K. Kirk et al. · 2021 · Circulation
  35. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
    Domingo Andrés Pascual-Figal, Antoni Bayés‐Genís, Paola Beltrán-Troncoso, Pedro Caravaca Pérez, Alicia Conde Martel, María G. Crespo‐Leiro, Juan F. Delgado, Javier Dı́ez, Francesç Formiga, Nicolás Manito · 2021 · Frontiers in Cardiovascular Medicine
  36. Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
    Kirsty McDowell, Paul I. Welsh, Kieran F. Docherty, David A. Morrow, Pardeep S. Jhund, Rudolf A. de Boer, Eileen O’Meara, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod et al. · 2022 · European Journal of Heart Failure
  37. A Clinician's Guide to the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure
    Michelle Maya Kittleson · 2022 · Journal of Cardiac Failure
  38. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics
    Miyesaier Abudureyimu, Xuanming Luo, Xiang Wang, James R. Sowers, Wenshuo Wang, Junbo Ge, Jun Tao Ren, Yingmei Zhang · 2022 · Journal of Molecular Cell Biology
  39. Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease
    Javier Morales, Yehuda Handelsman · 2023 · Journal of the American College of Cardiology
  40. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies
    Erberto Carluccio, Paolo Biagioli, Gianpaolo Reboldi, Anna Mengoni, Rosanna Lauciello, Cinzia Zuchi, Sandra D’Addario, Giuliana Bardelli, Giuseppe Ambrosio · 2023 · Cardiovascular Diabetology
  41. Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure
    Joshua D. Newman, Eileen O’Meara, Michael Böhm, Gianluigi Savarese, Patricia R. Kelly, Orly Vardeny, Larry A. Allen, Patrizio Lancellotti, Stephen S. Gottlieb, Zainab Z. Samad et al. · 2024 · Journal of the American College of Cardiology
  42. Contemporary pharmacological treatment and management of heart failure
    Biykem Bozkurt · 2024 · Nature Reviews Cardiology
  43. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis
    Nan Zhang, Yueying Wang, Gary Tse, Panagiotis G. Korantzopoulos, Κonstantinos P. Letsas, Qingpeng Zhang, Guangping Li, Gregory Y.H. Lip, Tong Liu · 2021 · European Journal of Preventive Cardiology
  44. Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
    Frank L.J. Visseren, François Mach, Yvo Michiel Smulders, David Carballo, Konstantinos C. Koskinas, Maria Bäck, Athanase Bénétos, Alessandro Biffi, José Manuel Boavida, Davide Capodanno et al. · 2022 · Revista Española de Cardiología
  45. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study
    Shigenori Hiruma, Fumika Shigiyama, Shinji Hisatake, Sunao Mizumura, Nobuyuki Shiraga, Masaaki Hori, Takanori Ikeda, Takahisa Hirose, Naoki Kumashiro · 2021 · Cardiovascular Diabetology
  46. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
    Peter R Rossing, Silvio E Inzucchi, Priya Vart, Niels Jongs, Kieran F. Docherty, Pardeep S Jhund, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr P. Ponikowski et al. · 2021 · The Lancet Diabetes & Endocrinology
  47. Effects of Empagliflozin on Erythropoiesis in Heart Failure: Data from the Empire HF Trial
    Camilla Fuchs Andersen, Massar Omar, Andreas Birkedal Glenthøj, Daniel El Fassi, Holger Jon Møller, Jørgen A. L. Kurtzhals, Bjarne Styrishave, Caroline Kistorp, Christian Tuxen, Mikael Kjær Poulsen et al. · 2022 · European Journal of Heart Failure
  48. Kidney glycolysis serves as a mammalian phosphate sensor that maintains phosphate homeostasis
    Wen Zhou, Petra Šimić, Iris Yuwen Zhou, Peter D. Caravan, Xavier Fernando Vela Parada, Donghai Wen, Onica L. Washington, Maria Shvedova, Kerry A. Pierce, Clary B. Clish et al. · 2023 · Journal of Clinical Investigation
  49. Predicting and preventing heart failure in type 2 diabetes
    Ambarish Pandey, Muhammad Shahzeb Khan, Kershaw V. Patel, Deepak L. Bhatt, Subodh Verma · 2023 · The Lancet Diabetes & Endocrinology
  50. Advances in the management of type 2 diabetes in adults
    Rodolfo Javier Galindo, Jennifer M. Trujillo, Cecilia C. Low Wang, Rozalina G. McCoy · 2023 · BMJ Medicine
  51. Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors
    Veraprapas Kittipibul, Zachary L. Cox, Supavit Chesdachai, Mona Fiuzat, JoAnn M. Lindenfeld, Robert John Mentz · 2024 · Journal of the American College of Cardiology
  52. Association between sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials
    Sfairopoulos, Dimitrios, Zhang, Nan, Wang, Yueying, Chen, Ziliang, Letsas, Konstantinos P, Tse, Gary, Li, Guangping, Lip, Gregory Y H, Liu, Tong, Korantzopoulos, Panagiotis · 2022 · EP Europace
  53. New progress in drugs treatment of diabetic kidney disease
    Wang, Junmin, Xiang, Hongjiao, Lu, Yifei, Wu, Tao, Ji, Guang · 2021 · Biomedicine & Pharmacotherapy
  54. Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
    Qutuba G. Karwi, Kim L. Ho, Simran Pherwani, Ezra B. Ketema, Qiuyu Sun, Gary D. Lopaschuk · 2021 · Cardiovascular Research
  55. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure
    Michael J. Szarek, Deepak L. Bhatt, Philippe Gabríel Steg, Christopher Paul Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia Breyer Lewis, Matthew C. Riddle, Adriaan A. Voors, Marco Metra et al. · 2021 · Annals of Internal Medicine
  56. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial
    Josephine Harrington, Jacob Allen Udell, W. Schuyler Jones, Stefan D. Anker, Deepak L. Bhatt, Mark Colquhoun Petrie, Ola Vedin, Mikhail Sumin, Isabella Zwiener, Adrian F. Hernandez et al. · 2022 · American Heart Journal
  57. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
    Staplin, Natalie, Roddick, Alistair J., Emberson, Jonathan, Reith, Christina, Riding, Alex, Wonnacott, Alexa, Kuverji, Apexa, Bhandari, Sunil, Baigent, Colin, Haynes, Richard et al. · 2021 · eClinicalMedicine
  58. Heart Failure in the Last Year: Progress and Perspective
    Daniela Tomasoni, Marianna Adamo, Markus S. Anker, Stephan von Haehling, Andrew J.S. Coats, Marco Metra · 2020 · ESC Heart Failure
  59. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
    Michael Böhm, Javed Butler, Gerasimos S Filippatos, João Pedro Ferreira, Stuart Pocock, Amr Abdin, Felix Mahfoud, Martina Brueckmann, Nicholas D. Gollop, Tomoko Iwata et al. · 2022 · Journal of the American College of Cardiology
  60. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025)
    Yusuke Ohya, Kimika Arakawa, Naoko Arata, Shuji Arima, Hisatomi Arima, K. Asayama, Yasuaki Dohi, Ako Fukami, Masato Furuhashi, Kenichi Goto et al. · 2026 · Hypertension Research
  61. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
    Francesco Prattichizzo, Paola de Candia, Antonio Ceriello · 2021 · Metabolism
  62. Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species
    Xiaoling Li, Gregor Römer, Raphaela P. Kerindongo, Jeroen Hermanides, Martin Albrecht, Markus Werner Hollmann, Coert Jozef Zuurbier, Benedikt Preckel, Nina Claudia Weber · 2021 · International Journal of Molecular Sciences
  63. Long-Term Follow-Up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients With Nonischemic Systolic Heart Failure on Mortality)
    Adelina Yafasova, Jawad H. Butt, Marie B. Elming, Jens C. Nielsen, Jens Haarbo, Lars Videbæk, Line L. Olesen, Flemming Hald Steffensen, Niels E. Bruun, Hans Eiskjær et al. · 2021 · Circulation
  64. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
    Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, Ele Ferrannini, Michael Albrecht Nauck, Soo Kyung Lim · 2022 · Trends in Endocrinology and Metabolism
  65. Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench
    Xin Chen, Carl‐Friedrich Hocher, Linghong Shen, Bernhard Karl Krämer, Berthold Hocher · 2023 · American Journal of Physiology-Cell Physiology
  66. SGLT2 Inhibitors, Functional Capacity, and Quality of Life in Patients With Heart Failure
    Michael Gao, Kirtipal Bhatia, Arjun B. Kapoor, Juan J. Badimón, Sean Pinney, DONNA M. MANCINI, Carlos G. Santos‐Gallego, Anuradha Lala · 2024 · JAMA Network Open
  67. Causal inference in health and disease: a review of the principles and applications of Mendelian randomization
    Catherine Elizabeth Lovegrove, Sarah Howles, Dominic Furniss, Michael Vaclav Holmes · 2024 · Journal of Bone and Mineral Research
  68. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
    Darren K. McGuire, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, DAVID H. FITCHETT, Stefan D. Anker, Stuart Pocock, Stefan Kaspers, Jyothis Thomas George, Maximilian von Eynatten et al. · 2020 · The Lancet Diabetes & Endocrinology
  69. Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure
    Andreas Daiber, Ioanna Andreadou, Matthias Walter Oelze, Sean M. Davidson, Derek John Hausenloy · 2020 · Free Radical Biology and Medicine
  70. Stress hyperglycemia, cardiac glucotoxicity, and critically ill patient outcomes current clinical and pathophysiological evidence
    Marc Scheen, Raphaël Giraud, Karim Bendjelid · 2021 · Physiological Reports
  71. Effects of Sodium‐Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice
    Dominique Croteau, Ivan Luptak, Jordan M. Chambers, Ion A. Hobai, Marcello Panagia, David Richard Pimentel, Deborah A. Siwik, Fuzhong Qin, Wilson S. Colucci · 2021 · Journal of the American Heart Association
  72. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
    Melanie Jane Davies, Heinz Drexel, François R. Jornayvaz, Zoltan Pataky, Petar M Seferovic, Christoph Wanner · 2022 · Cardiovascular Diabetology
  73. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
    Orly Vardeny, James Chen-Tson Fang, Akshay Suvas Desai, Pardeep S. Jhund, Brian Lee Claggett, Muthiah Vaduganathan, Rudolf A. de Boer, Adrian F. Hernandez, Carolyn S.P. Lam, Silvio E. Inzucchi et al. · 2022 · Nature Medicine
  74. Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart
    Gaetano Santulli, Fahimeh Varzideh, Imma Forzano, Scott Maxwell Wilson, Luigi Salemme, Antonio De Donato, Angela Lombardi, Antonio Rainone, Luigi Nunziata, Stanislovas S. Jankauskas et al. · 2023 · Hypertension
  75. UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE
    Alistair Roddick, Alexa Wonnacott, David R. Webb, Angela Watt, Michael A. Watson, Natalie Staplin, Alex Riding, Eirini Lioudaki, Apexa Kuverji, Mohsen El Kossi et al. · 2023 · BMC Nephrology
  76. Cardiorenal Syndrome in the Hospital
    Wendy I. McCallum, Mark J. Sarnak · 2023 · Clinical Journal of the American Society of Nephrology
  77. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial
    Sharma, Abhinav, Ferreira, João Pedro, Zannad, Faiez, Pocock, Stuart J., Filippatos, Gerasimos, Pfarr, Egon, Petrini, Michaela, Kraus, Bettina J., Wanner, Christoph, Packer, Milton et al. · 2023 · European Journal of Heart Failure
  78. SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
    Pasquale Paolisso, Marta Belmonte, Emanuele Gallinoro, Roberto Scarsini, Luca Bergamaschi, Leonardo Portolan, Matteo Armillotta, Giuseppe Esposito, Elisabetta Moscarella, Giovanni Benfari et al. · 2024 · Cardiovascular Diabetology
  79. Empagliflozin in Patients with Chronic Kidney Disease
    Brendon Lange Neuen, Robert A Fletcher, Hiddo J L Heerspink · 2023 · New England Journal of Medicine
  80. Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial
    Ashish Sarraju, Jingwei Li, Christopher Paul Cannon, Tara I. Chang, Rajiv Agarwal, George L. Bakris, David M. Charytan, Dick de Zeeuw, Tom Greene, Hiddo J.L. Heerspink et al. · 2020 · American Heart Journal
  81. Renal protection in chronic heart failure: focus on sacubitril/valsartan
    Roberto Pontremoli, Claudio Borghi, Pasquale Perrone Filardi · 2021 · European Heart Journal - Cardiovascular Pharmacotherapy
  82. From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
    Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A. Leiter, Antonio Ceriello, Ralph Anthony DeFronzo, Itamar Raz · 2021 · Cardiovascular Diabetology
  83. Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
    Zhaoyang Hu, Feng Ju, Lei Du, Geoffrey Winston Abbott · 2021 · Cardiovascular Diabetology
  84. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
    Kanie, T, Mizuno, A, Takaoka, Y, Suzuki, T, Yoneoka, D, Nishikawa, Y, Tam, WWS, Morze, J, Rynkiewicz, A, Xin, Y et al. · 2021 · UCL Discovery (University College London)
  85. Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome
    Konrad Urbanek, Donato Cappetta, Gabriella Bellocchio, Maria Antonietta Coppola, Paola Imbrici, Marialucia Telesca, Maria Donniacuo, Maria Antonietta Riemma, Elena Mele, Eleonora Cianflone et al. · 2022 · Pharmacological Research
  86. Contemporary Guideline-Directed Medical Therapy in De Novo, Chronic, and Worsening Heart Failure Patients: First Data from the TITRATE-HF Study
    Jishnu Malgie, Mariëlle I Wilde, Pascal R.D. Clephas, Mireille E. Emans, Stefan Koudstaal, Jeroen Schaap, Arend Mosterd, Jan van Ramshorst, Alexander J. Wardeh, Sandra Sanders‐van Wijk et al. · 2024 · European Journal of Heart Failure
  87. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes
    Matthew M.Y. Lee, Nazim Ghouri, Darren K. McGuire, Martin K. Rutter, Naveed A. Sattar · 2021 · Diabetes Care
  88. Metabolic Rewiring and Communication: An Integrative View of Kidney Proximal Tubule Function
    Maria Chrysopoulou, Markus Matthias Rinschen · 2023 · Annual Review of Physiology
  89. Cardiovascular and Kidney Risks in Individuals With Type 2 Diabetes: Contemporary Understanding With Greater Emphasis on Excess Adiposity
    Sattar, Naveed, Presslie, Calum, Rutter, Martin K., McGuire, Darren K. · 2024 · Diabetes Care
  90. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis
    Alberto Aimo, Konstantinos Pateras, Kimon S. Stamatelopoulos, Antoni Bayés‐Genís, Carlo Lombardi, Claudio Passino, Michele Emdin, Georgios A. Georgiopoulos · 2020 · Cardiovascular Drugs and Therapy
  91. Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
    Gloria M. Gager, Dirk von Lewinski, Harald Sourij, Bernd Jilma, Ceren Eyileten, KJ Filipiak, Martin Hülsmann, Jacek Kubica, Marek A Postula, Jolanta Maria Siller-Matula · 2021 · Biomedicine & Pharmacotherapy
  92. Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
    Teresa Salvatore, Alfredo Caturano, Raffaele Galiero, Anna Di Martino, Gaetana Albanese, Erica Vetrano, Celestino Sardu, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso · 2021 · Biomedicines
  93. Real-World Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure and Reduced Ejection Fraction: Data from the Swedish Heart Failure Registry
    Davide Stolfo, Lars H. Lund, Lina Benson, Felix Lindberg, Giulia Ferrannini, Ulf Dahlström, Gianfranco Sinagra, Giuseppe M.C. Rosano, Gianluigi Savarese · 2023 · European Journal of Heart Failure
  94. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
    Matthias Rau, Kirsten Thiele, Niels‐Ulrik Korbinian Hartmann, Alexander Schuh, Ertunc Altiok, Julia Möllmann, András P. Keszei, Michael Böhm, Nikolaus Marx, Michael Lehrke · 2021 · Cardiovascular Diabetology
  95. Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs
    Kraler, Simon, Libby, Peter, Evans, Paul C., Akhmedov, Alexander, Schmiady, Martin O., Reinehr, Michael, Camici, Giovanni G., Lüscher, Thomas F. · 2021 · Arteriosclerosis, Thrombosis, and Vascular Biology
  96. Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na+?
    Maximilian Trum, Johannes Riechel, Stefan Wagner · 2021 · International Journal of Molecular Sciences
  97. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study
    Kirsten Thiele, Matthias Rau, Niels‐Ulrik Korbinian Hartmann, Julia Möllmann, Joachim Jankowski, Michael Böhm, András P. Keszei, Nikolaus Marx, Michael Lehrke · 2021 · Diabetes Obesity and Metabolism
  98. Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling
    Ke Lin, Na Yang, Wu Luo, Jinfu Qian, Weiwei Zhu, Shiju Ye, Chen-xin Yuan, Diyun Xu, Guang Liang, Weijian Huang et al. · 2022 · Acta Pharmacologica Sinica
  99. Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure
    Matteo Armillotta, Francesco Angeli, Pasquale Paolisso, Marta Belmonte, Emanuel Raschi, Guido Di Dalmazi, Sara Amicone, Lisa Canton, Damiano Fedele, Nicole Suma et al. · 2025 · Pharmacology & Therapeutics
  100. Financial burden, distress, and toxicity in cardiovascular disease
    Samuel D. Slavin, Rohan Khera, S. Yousuf Zafar, Khurram Nasir, Haider Javed Warraich · 2021 · American Heart Journal